Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05142696 · ClinicalTrials.gov registry record · Phase 1

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
20
Study locations

NCT05142696: Active Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

NCT05142696 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 24 participants, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05142696, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
20
Study locations

Study Summary

This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.

Primary Outcome

A dose-limiting toxicity (DLT) is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications with an onset within the first cycle of initiation of \[177Lu\]Lu-DOTA-TATE treatment. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 5.0 will be used for AE grading.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Atezolizumab
  • DRUG [177Lu]Lu-DOTA-TATE
  • DRUG [68Ga]Ga-DOTA-TATE
  • OTHER Carboplatin
  • OTHER Etoposide

Study Locations (20)

Other

  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Beijing
  • Novartis Investigative Site - Shanghai
  • Novartis Investigative Site - Olomouc
  • Novartis Investigative Site - Bron
  • Novartis Investigative Site - Lille
  • Novartis Investigative Site - Marseille
  • Novartis Investigative Site - Montpellier

District of Columbia

  • Georgetown University Lombardi Cancer Center - Washington D.C.

Florida

  • Advent Health Cancer Institute - Orlando

Georgia

  • University Cancer and Blood Center LLC - Athens

Kentucky

  • University of Kentucky - Lexington

Missouri

  • St. Louis University - St Louis

New Jersey

  • Hackensack Meridian Health - Edison

Ohio

  • University Hospitals Of Cleveland - Cleveland

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-07-13
Est. Completion 2029-03-23
Phase Phase 1
Novartis Pharmaceuticals

1,375 total trials

What the registry record for NCT05142696 still lists

NCT05142696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.

NCT05142696 names 20 study sites across 13 states, led by Other, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT05142696 about?

NCT05142696 is a clinical study titled "A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab". This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The stu...

What is the current status of trial NCT05142696?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-07-13. Estimated completion is 2029-03-23.

What conditions does trial NCT05142696 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT05142696?

The interventions under investigation include: Atezolizumab (DRUG), [177Lu]Lu-DOTA-TATE (DRUG), [68Ga]Ga-DOTA-TATE (DRUG), Carboplatin (OTHER), Etoposide (OTHER).

Who is sponsoring clinical trial NCT05142696?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05142696 being conducted?

This trial has 20 study locations across District of Columbia, Florida, Georgia, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05142696's enrollment target sits among peer trials

24 21st of 25 higher than 4 of 25 other Extensive-stage Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05142696, the US trial registry maintained by the National Library of Medicine. NCT05142696 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.